Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes

NEXT STORY
HUTCHMED announces savolitinib approved in China for patients with lung cancer with MET exon 14 skipping alterations
PREV STORY
NGS Based RNA Sequencing Market Worth US$ 6874 Million by 2031: Visiongain Research Inc.
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Helsinn Provides Grant for ESMO’s Preceptorship Programme for Supportive and Palliative Care

author_avatar
NASDAQ Market News

Novartis JULIET trial of Kymriah demonstrates more than one-year durability of responses in adults with relapsed or refractory DLBCL

Overall response rate was 52% and median duration of response was not reached at ...

author_avatar
NASDAQ Market News

Infectious Disease Diagnostics Market Worth $42.85 billion by 2027- Exclusive Report by Meticulous Research® Covering Emerging Growth Factors, Latest Trends and Forecasts, and Pre and Post COVID-19 Estimates

author_avatar
NASDAQ Market News